|
|||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
Rights Issue (Via Preemptive Right)
|
|||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
Other Aspects To Be Notified
|
|||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
|
Additional Explanations
|
|||||||||||||||||||||||||||||||||
|
The disclosure we made on 14.06.2023 at 11:14 has been revised.
Zorlu Enerji has been notified that the Prospectus for increasing the Company's paid-in capital from TL 2,500 mn to TL 5,000 mn via a TL 2,500 mn rights issue has been approved by the Capital Markets Board of Turkey with the Board's letter dated 08.06.2023 and numbered E-29833736-105.01.01.01-38457.
Accordingly;
- Shareholders will have the right to subscribe to the rights issue at the rate of 100% of the shares they hold.
- The subscription period will be 15 days and will commence on June 15, 2023 and end on July 3, 2023, in accordance with the principles set forth in the Prospectus. The last day of the subscription period is normally June 28, 2023, but because of a public holiday on this date, the subscription period will end on the following business day, which is July 3, 2023.
- The subscription price for the rights issue is TL 1 per share, which is the nominal value for 100 shares (1 lot).
- The Prospectus for Zorlu Enerji's rights issue is available on the Public Disclosure Platform ( www.kap.gov.tr ) and on the websites of Zorlu Enerji's ( www.zorluenerji.com.tr ) and Deniz Yatırım Menkul Kıymetler AŞ (the intermediary for the issue) ( www.denizyatirim.com ).
- The unexercised rights will be offered for sale, at the price to be formed in the market and not remaining below the nominal value, in the Primary Market of Borsa Istanbul for 2 business days following the expiration of the subscription period.
- The major shareholder Zorlu Holding has pledged to purchase the remaining shares (if any) at the end of the offering.
This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.
|
|||||||||||||||||||||||||||||||||